BCRX Annual EBIT
-$117.99 M
+$27.30 M+18.79%
31 December 2023
Summary:
As of January 22, 2025, BCRX annual earnings before interest & taxes is -$117.99 million, with the most recent change of +$27.30 million (+18.79%) on December 31, 2023. During the last 3 years, it has risen by +$50.32 million (+29.90%). BCRX annual EBIT is now -2266.66% below its all-time high of -$3.94 million.BCRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Quarterly EBIT
$11.38 M
-$850.00 K-6.95%
30 September 2024
Summary:
As of January 22, 2025, BCRX quarterly earnings before interest & taxes is $11.38 million, with the most recent change of -$850.00 thousand (-6.95%) on September 30, 2024. Over the past year, it has increased by +$49.96 million (+129.50%). BCRX quarterly EBIT is now -24.56% below its all-time high of $15.09 million, reached on December 31, 2009.BCRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX TTM EBIT
-$25.48 M
+$19.86 M+43.80%
30 September 2024
Summary:
As of January 22, 2025, BCRX TTM earnings before interest & taxes is -$25.48 million, with the most recent change of +$19.86 million (+43.80%) on September 30, 2024. Over the past year, it has increased by +$92.52 million (+78.41%). BCRX TTM EBIT is now -1598.33% below its all-time high of -$1.50 million, reached on March 31, 1994.BCRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.8% | +129.5% | +78.4% |
| 3 y3 years | +29.9% | +125.5% | +85.9% |
| 5 y5 years | -28.1% | +132.9% | +73.7% |
BCRX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +18.8% | -7.0% | +122.7% | at high | +82.5% |
| 5 y | 5-year | -21.6% | +29.9% | -7.0% | +120.7% | at high | +86.2% |
| alltime | all time | -2266.7% | +29.9% | -24.6% | +120.7% | -1598.3% | +86.2% |
BioCryst Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $11.38 M(-6.9%) | -$25.48 M(-43.8%) |
| June 2024 | - | $12.23 M(-216.4%) | -$45.33 M(-56.1%) |
| Mar 2024 | - | -$10.51 M(-72.8%) | -$103.23 M(-12.5%) |
| Dec 2023 | -$117.99 M(-18.8%) | -$38.58 M(+355.3%) | -$117.99 M(-5.2%) |
| Sept 2023 | - | -$8.47 M(-81.4%) | -$124.42 M(-5.9%) |
| June 2023 | - | -$45.67 M(+80.8%) | -$132.17 M(+9.7%) |
| Mar 2023 | - | -$25.27 M(-43.9%) | -$120.48 M(-17.1%) |
| Dec 2022 | -$145.29 M(+18.6%) | -$45.01 M(+177.4%) | -$145.29 M(+49.7%) |
| Sept 2022 | - | -$16.22 M(-52.3%) | -$97.03 M(-22.7%) |
| June 2022 | - | -$33.98 M(-32.1%) | -$125.49 M(+3.5%) |
| Mar 2022 | - | -$50.08 M(-1639.0%) | -$121.22 M(-1.1%) |
| Dec 2021 | -$122.52 M(-27.2%) | $3.25 M(-107.3%) | -$122.52 M(-32.2%) |
| Sept 2021 | - | -$44.69 M(+50.4%) | -$180.65 M(+1.0%) |
| June 2021 | - | -$29.70 M(-42.2%) | -$178.84 M(-3.2%) |
| Mar 2021 | - | -$51.38 M(-6.4%) | -$184.83 M(+10.0%) |
| Dec 2020 | -$168.31 M(+73.5%) | -$54.88 M(+28.0%) | -$168.00 M(+49.1%) |
| Sept 2020 | - | -$42.88 M(+20.1%) | -$112.65 M(+8.0%) |
| June 2020 | - | -$35.69 M(+3.3%) | -$104.32 M(+1.1%) |
| Mar 2020 | - | -$34.55 M(-7530.5%) | -$103.23 M(+6.4%) |
| Dec 2019 | -$97.00 M(+5.4%) | $465.00 K(-101.3%) | -$97.00 M(-20.8%) |
| Sept 2019 | - | -$34.55 M(-0.1%) | -$122.49 M(+6.3%) |
| June 2019 | - | -$34.59 M(+22.1%) | -$115.19 M(+18.9%) |
| Mar 2019 | - | -$28.33 M(+13.2%) | -$96.85 M(+5.2%) |
| Dec 2018 | -$92.08 M(+60.9%) | -$25.02 M(-8.2%) | -$92.08 M(+9.1%) |
| Sept 2018 | - | -$27.25 M(+67.7%) | -$84.37 M(+20.3%) |
| June 2018 | - | -$16.25 M(-31.0%) | -$70.11 M(+2.1%) |
| Mar 2018 | - | -$23.56 M(+36.1%) | -$68.65 M(+20.0%) |
| Dec 2017 | -$57.22 M(+17.6%) | -$17.31 M(+33.2%) | -$57.22 M(+35.3%) |
| Sept 2017 | - | -$12.99 M(-12.2%) | -$42.28 M(+7.4%) |
| June 2017 | - | -$14.79 M(+22.1%) | -$39.35 M(-0.2%) |
| Mar 2017 | - | -$12.12 M(+410.9%) | -$39.41 M(-19.0%) |
| Dec 2016 | -$48.66 M(+28.7%) | -$2.37 M(-76.4%) | -$48.66 M(-22.9%) |
| Sept 2016 | - | -$10.06 M(-32.3%) | -$63.08 M(-5.0%) |
| June 2016 | - | -$14.86 M(-30.4%) | -$66.40 M(+46.5%) |
| Mar 2016 | - | -$21.36 M(+27.2%) | -$45.33 M(+19.9%) |
| Dec 2015 | -$37.82 M(-5.9%) | -$16.80 M(+25.5%) | -$37.82 M(+20.5%) |
| Sept 2015 | - | -$13.38 M(-315.6%) | -$31.38 M(+23.0%) |
| June 2015 | - | $6.21 M(-144.8%) | -$25.51 M(-43.5%) |
| Mar 2015 | - | -$13.85 M(+33.7%) | -$45.15 M(+12.3%) |
| Dec 2014 | -$40.19 M(+58.7%) | -$10.36 M(+37.8%) | -$40.19 M(+18.1%) |
| Sept 2014 | - | -$7.51 M(-44.0%) | -$34.02 M(+2.1%) |
| June 2014 | - | -$13.42 M(+50.9%) | -$33.32 M(+7.8%) |
| Mar 2014 | - | -$8.89 M(+112.4%) | -$30.90 M(+22.0%) |
| Dec 2013 | -$25.33 M(-26.4%) | -$4.19 M(-38.5%) | -$25.33 M(-18.3%) |
| Sept 2013 | - | -$6.81 M(-38.1%) | -$31.02 M(-5.3%) |
| June 2013 | - | -$11.01 M(+230.9%) | -$32.74 M(-0.3%) |
| Mar 2013 | - | -$3.33 M(-66.3%) | -$32.85 M(-4.6%) |
| Dec 2012 | -$34.41 M(-35.3%) | -$9.87 M(+15.7%) | -$34.41 M(-12.1%) |
| Sept 2012 | - | -$8.53 M(-23.2%) | -$39.17 M(-9.8%) |
| June 2012 | - | -$11.12 M(+127.2%) | -$43.44 M(-6.7%) |
| Mar 2012 | - | -$4.89 M(-66.6%) | -$46.57 M(-12.4%) |
| Dec 2011 | -$53.17 M(+57.1%) | -$14.63 M(+14.2%) | -$53.18 M(+10.0%) |
| Sept 2011 | - | -$12.80 M(-10.1%) | -$48.35 M(+3.9%) |
| June 2011 | - | -$14.24 M(+23.9%) | -$46.54 M(+9.2%) |
| Mar 2011 | - | -$11.50 M(+17.3%) | -$42.62 M(+25.9%) |
| Dec 2010 | -$33.85 M(+146.4%) | -$9.80 M(-10.8%) | -$33.85 M(+277.7%) |
| Sept 2010 | - | -$10.99 M(+6.4%) | -$8.96 M(+3.4%) |
| June 2010 | - | -$10.33 M(+278.5%) | -$8.67 M(+22.5%) |
| Mar 2010 | - | -$2.73 M(-118.1%) | -$7.08 M(-48.5%) |
| Dec 2009 | -$13.74 M | $15.09 M(-241.0%) | -$13.74 M(-27.8%) |
| Sept 2009 | - | -$10.70 M(+22.4%) | -$19.02 M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$8.74 M(-6.9%) | -$17.89 M(-20.6%) |
| Mar 2009 | - | -$9.39 M(-195.7%) | -$22.54 M(-17.0%) |
| Dec 2008 | -$27.16 M(-15.8%) | $9.80 M(-202.4%) | -$27.16 M(-32.8%) |
| Sept 2008 | - | -$9.57 M(-28.5%) | -$40.40 M(-5.4%) |
| June 2008 | - | -$13.38 M(-4.5%) | -$42.69 M(+15.7%) |
| Mar 2008 | - | -$14.02 M(+308.9%) | -$36.89 M(+54.9%) |
| Dec 2007 | -$32.28 M(-31.3%) | -$3.43 M(-71.1%) | -$23.81 M(-23.5%) |
| Sept 2007 | - | -$11.86 M(+56.4%) | -$31.12 M(-12.9%) |
| June 2007 | - | -$7.58 M(+705.9%) | -$35.72 M(-8.8%) |
| Mar 2007 | - | -$940.80 K(-91.2%) | -$39.15 M(-16.7%) |
| Dec 2006 | -$46.98 M(+72.9%) | -$10.74 M(-34.8%) | -$46.98 M(+7.4%) |
| Sept 2006 | - | -$16.46 M(+49.4%) | -$43.73 M(+24.2%) |
| June 2006 | - | -$11.02 M(+25.7%) | -$35.20 M(+16.9%) |
| Mar 2006 | - | -$8.77 M(+17.1%) | -$30.11 M(+10.8%) |
| Dec 2005 | -$27.18 M(+24.9%) | -$7.49 M(-5.5%) | -$27.18 M(+8.2%) |
| Sept 2005 | - | -$7.93 M(+33.6%) | -$25.12 M(+10.9%) |
| June 2005 | - | -$5.93 M(+1.7%) | -$22.64 M(+3.2%) |
| Mar 2005 | - | -$5.83 M(+7.4%) | -$21.94 M(+0.9%) |
| Dec 2004 | -$21.75 M(+59.0%) | -$5.43 M(-0.4%) | -$21.75 M(+5.8%) |
| Sept 2004 | - | -$5.45 M(+4.2%) | -$20.55 M(+11.0%) |
| June 2004 | - | -$5.23 M(-7.3%) | -$18.51 M(+12.0%) |
| Mar 2004 | - | -$5.64 M(+33.4%) | -$16.53 M(+20.9%) |
| Dec 2003 | -$13.68 M(-26.9%) | -$4.23 M(+24.1%) | -$13.68 M(-4.6%) |
| Sept 2003 | - | -$3.41 M(+4.8%) | -$14.33 M(-0.0%) |
| June 2003 | - | -$3.25 M(+16.6%) | -$14.34 M(-12.2%) |
| Mar 2003 | - | -$2.79 M(-42.9%) | -$16.34 M(-14.8%) |
| Dec 2002 | -$18.70 M(+275.2%) | -$4.88 M(+43.0%) | -$19.16 M(+13.5%) |
| Sept 2002 | - | -$3.42 M(-34.9%) | -$16.88 M(+24.3%) |
| June 2002 | - | -$5.25 M(-6.6%) | -$13.59 M(+64.0%) |
| Mar 2002 | - | -$5.62 M(+115.6%) | -$8.28 M(+58.3%) |
| Dec 2001 | -$4.99 M(-49.3%) | -$2.60 M(+2088.7%) | -$5.23 M(-7.9%) |
| Sept 2001 | - | -$119.00 K(-316.4%) | -$5.68 M(-24.7%) |
| June 2001 | - | $55.00 K(-102.1%) | -$7.55 M(-24.8%) |
| Mar 2001 | - | -$2.57 M(-16.0%) | -$10.04 M(+1.6%) |
| Dec 2000 | -$9.83 M(+21.4%) | -$3.06 M(+54.0%) | -$9.88 M(+7.1%) |
| Sept 2000 | - | -$1.98 M(-18.5%) | -$9.23 M(-6.2%) |
| June 2000 | - | -$2.43 M(+0.9%) | -$9.85 M(+24.3%) |
| Mar 2000 | - | -$2.41 M(+0.5%) | -$7.92 M(-1.1%) |
| Dec 1999 | -$8.10 M(+35.0%) | -$2.40 M(-7.7%) | -$8.01 M(+8.1%) |
| Sept 1999 | - | -$2.60 M(+411.6%) | -$7.41 M(+207.6%) |
| June 1999 | - | -$508.00 K(-79.7%) | -$2.41 M(-52.8%) |
| Mar 1999 | - | -$2.50 M(+38.9%) | -$5.10 M(-12.1%) |
| Dec 1998 | -$6.00 M(-51.2%) | -$1.80 M(-175.0%) | -$5.80 M(-21.6%) |
| Sept 1998 | - | $2.40 M(-175.0%) | -$7.40 M(-41.3%) |
| June 1998 | - | -$3.20 M(0.0%) | -$12.60 M(+5.9%) |
| Mar 1998 | - | -$3.20 M(-5.9%) | -$11.90 M(-2.5%) |
| Dec 1997 | -$12.30 M(+41.4%) | -$3.40 M(+21.4%) | -$12.20 M(+1.7%) |
| Sept 1997 | - | -$2.80 M(+12.0%) | -$12.00 M(+3.4%) |
| June 1997 | - | -$2.50 M(-28.6%) | -$11.60 M(+11.5%) |
| Mar 1997 | - | -$3.50 M(+9.4%) | -$10.40 M(+18.2%) |
| Dec 1996 | -$8.70 M(-4.4%) | -$3.20 M(+33.3%) | -$8.80 M(+11.4%) |
| Sept 1996 | - | -$2.40 M(+84.6%) | -$7.90 M(+3.9%) |
| June 1996 | - | -$1.30 M(-31.6%) | -$7.60 M(-5.0%) |
| Mar 1996 | - | -$1.90 M(-17.4%) | -$8.00 M(-11.1%) |
| Dec 1995 | -$9.10 M(+33.8%) | -$2.30 M(+9.5%) | -$9.00 M(+4.7%) |
| Sept 1995 | - | -$2.10 M(+23.5%) | -$8.60 M(+4.9%) |
| June 1995 | - | -$1.70 M(-41.4%) | -$8.20 M(-2.4%) |
| Mar 1995 | - | -$2.90 M(+52.6%) | -$8.40 M(+20.0%) |
| Dec 1994 | -$6.80 M | -$1.90 M(+11.8%) | -$7.00 M(+37.3%) |
| Sept 1994 | - | -$1.70 M(-10.5%) | -$5.10 M(+50.0%) |
| June 1994 | - | -$1.90 M(+26.7%) | -$3.40 M(+126.7%) |
| Mar 1994 | - | -$1.50 M | -$1.50 M |
FAQ
- What is BioCryst Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual EBIT year-on-year change?
- What is BioCryst Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly EBIT year-on-year change?
- What is BioCryst Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM EBIT year-on-year change?
What is BioCryst Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of BCRX is -$117.99 M
What is the all time high annual EBIT for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual earnings before interest & taxes is -$3.94 M
What is BioCryst Pharmaceuticals annual EBIT year-on-year change?
Over the past year, BCRX annual earnings before interest & taxes has changed by +$27.30 M (+18.79%)
What is BioCryst Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of BCRX is $11.38 M
What is the all time high quarterly EBIT for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly earnings before interest & taxes is $15.09 M
What is BioCryst Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, BCRX quarterly earnings before interest & taxes has changed by +$49.96 M (+129.50%)
What is BioCryst Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of BCRX is -$25.48 M
What is the all time high TTM EBIT for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM earnings before interest & taxes is -$1.50 M
What is BioCryst Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, BCRX TTM earnings before interest & taxes has changed by +$92.52 M (+78.41%)